News

Monopar Therapeutics Reveals Promising ALXN1840 Findings

Monopar Therapeutics Reveals Promising ALXN1840 Findings

Monopar Therapeutics Announces New Data on ALXN1840

Monopar Therapeutics Inc. (NASDAQ: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, has announced groundbreaking findings regarding the long-term neurological efficacy and safety of its investigational therapy ALXN1840, targeting Wilson disease. The data is set to be showcased at the prestigious American Neurological Association (ANA) Annual Meeting, solidifying Monopar's commitment to addressing critical health challenges.

Details of the Upcoming Presentation

Dr. Matthew Lorincz, a respected Professor of Neurology and Co-Director of the esteemed Wilson Disease Center of Excellence, will lead the presentation at the ANA event. The detailed findings are anticipated to create significant interest within the medical community.

Long-Term Efficacy and Safety Analysis

The presentation will highlight a comprehensive analysis derived from pooled efficacy outcomes from three independent clinical trials involving 255 patients, alongside safety data from an additional clinical trial of 266 participants. The median duration of treatment with ALXN1840 was approximately 2.6 years, underscoring the viability of long-term treatment protocols.

Key Findings on Neurological Benefits

The findings of the new data emphasize substantial long-term neurological benefits offered by ALXN1840. Notably, these results follow previously reported findings on hepatic and systemic efficacy, reinforcing ALXN1840's dual potential in treating Wilson disease's neurological and hepatic manifestations.

Significant Results and Insights

Among the key conclusions presented at the ANA, the following stand out:

Sustained Neurological Improvement: Neurological enhancements, as assessed using the Unified Wilson Disease Rating Scale (UWDRS), were significant from baseline and have been maintained over a span of six years.

Crossover Benefit: Notably, patients transitioning from standard of care to ALXN1840 demonstrated additional neurological improvements, with many experiencing a reversal of symptoms after transitioning.

Enhanced Psychiatric Outcomes: Sustained psychiatric improvements were also recorded over several years using the Brief Psychiatric Rating Scale (BPRS). This data reflects the therapy's overall impact on patients' mental health.

Consistency Across Trials: The neurological benefits were consistently observed across multiple independent studies, suggesting reliable efficacy.

Favorable Safety Profile: Impressively, out of more than 645 patient-years of treatment with ALXN1840, fewer than 1% of patients experienced drug-related serious adverse events, underscoring a solid safety profile.

Expert Insight

Dr. Matthew Lorincz expressed his optimism regarding these findings, stating, "These results are very encouraging for Wilson disease patients, including for those already on standard of care treatment." His comments highlight the potential advancements in treatment options available for this group.

About Monopar Therapeutics Inc.

Monopar Therapeutics is not only advancing ALXN1840 for Wilson disease but is also exploring cutting-edge radiopharmaceutical programs. These include the Phase 1-stage MNPR-101-Zr aimed at imaging advanced cancers, and ongoing efforts in the treatment of advanced cancers through MNPR-101-Lu and MNPR-101-Ac225.

Frequently Asked Questions

What is the significance of the data presented by Monopar?

The data showcases substantial long-term neurological benefits and safety profiles for ALXN1840, offering hope for Wilson disease patients.

When will the new findings be presented?

The results will be presented at the upcoming American Neurological Association Annual Meeting.

What is ALXN1840 used for?

ALXN1840 is an investigational therapy developed to treat Wilson disease, focusing on neurological and hepatic effects.

Who is presenting the findings?

Dr. Matthew Lorincz, a leading expert in neurology, will present the findings at the conference.

What future developments can be expected from Monopar?

Monopar Therapeutics is advancing its pipeline focused on innovative therapies for challenging medical conditions, including various cancer treatments and Wilson disease.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Insight Into Midland TX Real Estate Sales Timing

Updated Category News Views 92

How Fast Do Homes Move in Midland? This ain't my first rodeo predicting the real estate rollercoaster in Texas. Midland's housing market is one nifty beast—homes can either sell like hotcakes or just sit gathering dust. You got HelloNation pulling in DeLaura Gammage, a pro who knows the terrain like the back of her hand, to spell out the why and how long it'll take to...

Continue Reading
Rakuten Medical Fires Up Phase 1 Trial for RM-0256 Therapy

Updated Category News Views 272

Taking Aim at Refractory Tumors in Japan Get this—Rakuten Medical is stepping into the ring with their new cancer-busting tactic, RM-0256 photoimmunotherapy, right in Japan. We're talking about a Phase 1 trial that'll throw a new kind of punch at solid tumors, specifically targeting troublesome skin cancers that don’t seem to play nice with current treatments. Now,...

Continue Reading
Grupo Supervielle's Q3 2026: Back to Growth Path

Updated Category News Views 49

Mounting Momentum in Loans and Asset Quality Grupo Supervielle, the Argentine financial player, has been tinkering with its gears to navigate the bumpy roads of 2026. In the third quarter, the company reports a gentle uptick in net loans—up 1.3% sequentially. This was particularly felt in September, with loans increasing 3.7%. Holding Their Own Against the Industry...

Continue Reading
AvidXchange Acquisition Faces Fairness Investigation

Updated Category News Views 233

Unpacking the AvidXchange Turmoil Staring at the ticker tape feels like watching a drama unfold, and today it's all about AvidXchange Holdings, Inc. (NASDAQ: AVDX). Levi & Korsinsky, LLP has launched an investigation into the fairness of its acquisition, and let me tell you, when the suits start poking around, it means someone smells a rat. The deal in question? A buyout...

Continue Reading
Sinch Appoints Jonas Dahlberg as New CEO: A Strategic Move

Updated Category News Views 74

A Change at the Helm: Dahlberg Takes Charge Here we go, folks—Sinch, that global powerhouse in customer communications, just got itself a new captain. Jonas Dahlberg is now officially the CEO, after warming the acting CEO seat since June. This ain't your ordinary office shuffle. It's a calculated chess move in the high-stakes tech world. Dahlberg's Path to the Top This...

Continue Reading
Sharon Stuart's Quest for Her Hidden Origins

Updated Category News Views 123

Delving Into Identity: A Personal Odyssey In a world where everyone seems to be searching for something, Sharon Stuart's quest is etched with the raw need to uncover her real origins. Abandoned as a newborn in the gritty streets of Oakland, she grew up grappling with looming questions about what made her who she is. Her journey is captured in her memoir, "Existing Without...

Continue Reading
Crocs to Present at Key Industry Conferences

Updated Category News Views 148

Crocs Set to Step into the Spotlight Alright, if there's one thing about Crocs, Inc. (NASDAQ: CROX) that never fails to surprise, it's how they constantly keep everyone on their toes. The iconic casual footwear brand with its whimsical, love-it-or-hate-it reputation is strapping in for not one but two hefty conferences. They've circled November 19 and December 1, 2026, on...

Continue Reading
Sabre Unveils AI Travel Tech: A Bold New Frontier

Updated Category News Views 92

Sabre's Game-Changing AI Travel Integration I'm no stranger to bold moves in the travel industry, but what Sabre's rolling out tomorrow might just be the biggest leap we've seen in a while. They're unleashing what's called the first global travel plug-in within Grok Bot, marking a significant shake-up in the travel tech sphere. Too many tech upgrades in this business...

Continue Reading
Chicken Production Rises Amid Meat Market Shifts

Updated Category News Views 187

Protein Markets Scramble: Chicken Production Climbs Here’s a tasty tidbit that might just have investors reeling: the USDA says chicken production will be cruising on the up, whereas beef is taking a bit of a backseat. Yep, the big birds are flying higher, and the cows, well, they're just mooing a little softer. And what's that mean for big players like Tyson...

Continue Reading
PolyBio Convergence Summit Tackles Aging, Chronic Illness

Updated Category News Views 211

Kicking Off The Convergence: Pathogens in Focus Here's a gathering that's set to challenge how we think about lingering illnesses and aging. PolyBio Research Foundation is bringing a powerhouse of brains to the table with their inaugural Convergence Summit. It's more than just science talk; it's a chance to push boundaries in understanding how pathogens stick around and...

Continue Reading

Top 5 Most Recently Viewed Articles

Atlantic International Corp. Achieves Major Contract Success

Updated Category News Views 124

Atlantic International Corp. Secures Major Contract for Growth Atlantic International Corp. (Nasdaq: ATLN), a prominent player in the field of strategic staffing, recently achieved a significant milestone through its subsidiary, Lyneer Staffing Solutions. This achievement comes in the form of a multi-million dollar manufacturing contract with a leading food manufacturer....

Continue Reading
Santa Cruz County's Bold Move Against Cigarette Filters

Updated Category News Views 144

Santa Cruz County's Bold Action Against Cigarette Filters In a landmark decision, Santa Cruz County has become the first jurisdiction globally to implement a ban on the sale of cigarettes with filters. This crucial measure aligns perfectly with the upcoming World No Tobacco Day, highlighting the county's commitment to both public health and environmental sustainability....

Continue Reading
OceanaGold Embraces New Fast-Track Approvals for Growth

Updated Category News Views 154

OceanaGold Welcomes New Fast-track Approvals Act OceanaGold Corporation (TSX: OGC) (OTCQX: OCANF) has embraced the recent passing of the Fast-track Approvals Act by the New Zealand Parliament. This important legislative move is designed to streamline the consenting process for regionally and nationally significant infrastructure and development projects. With this new...

Continue Reading
Why Debt Repayment Spreadsheets Fail and How to Get Out of Debt

Updated Category Personal Finance Views 113

We have all been told the same basic formula for clearing negative balances: list your liabilities from smallest to largest, choose between the avalanche or snowball method, and cut your spending to the bone. On paper, a debt payoff journey looks like a straightforward mathematical equation. But if you have ever spent a weekend building a beautiful, co

Continue Reading
Elis Reports Own Shares Trading Activity and Future Plans

Updated Category News Views 232

Elis Shares Trading Activity Overview Elis has recently engaged in noteworthy trading activities concerning its own shares. As part of this initiative, Elis has executed buybacks of its own shares under a designated program authorized by the company's shareholders. Details of Recent Share Buybacks According to updated regulations on share buybacks, Elis conducted several...

Continue Reading